Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost February 23, 20268:15 PM UTCUpdated ago By Ahmed Aboulenein U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., November 10, 2025.... Purchase Licensing Rights, opens new tab Read ...

Merck creates separate oncology arm ahead of Keytruda patent loss - Invezz# Merck creates separate oncology arm ahead of Keytruda patent loss[Health & pharma]Author[Vatsala Gaur]Feb 23, 2026, 14:11 PM- Company banks on pipeline growth and recent acquisitions to offset pressure.- Leadership changes aim to prepare for Keytruda's 2028 patent expiry.- Merck splits its human-health business into oncology and specialty divisions.Merck said on Monday that it will split its human-health operations into two separate ...

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is based on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veeva Systems Inc. - Veeva Systems Inc. (NYSE:VEEV) is a technology company providing a cloud-based software platform for the life sciences industry, with a market capitalization of $29.64 billion [2] - The stock of Veeva Systems Inc. experienced a one-month return of -19.57% and a 52-week decline of 20.26% [2] - Veeva Systems was identified as a detractor from the Fund's performance in Q4 2025, despite its strong market position and innovative solutions in the life sciences sector [3] - The company's offerings include Veeva Customer Relationship Management (CRM) and Veeva Vault, which have established a dominant market position and present opportunities for growth in clinical applications [3] - Veeva's client base includes major global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly, Merck, and Novartis [3]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Insights - Gossamer Bio's experimental drug for a serious lung and heart condition failed to meet the primary endpoint in a late-stage clinical trial [1] Company Summary - Gossamer Bio announced the failure of its experimental drug in a late-stage study, which is a significant setback for the company [1]

The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution. ...

每经AI快讯，2月23日，默克公司设立独立癌症业务部门后，该公司股价盘前上涨1%。 ...

Core Viewpoint - Merck is restructuring its human-health business into two divisions to mitigate the impact of the impending patent loss of its leading drug, Keytruda [1] Group 1: Business Restructuring - Merck will create a separate division for its cancer drugs, which will include Keytruda [1] - The other division will focus on non-cancer products [1] Group 2: Market Context - The restructuring is a strategic response to the pressures associated with the patent expiration of Keytruda, which is Merck's top-selling drug [1]

Core Viewpoint - The drugmaker is restructuring its pharmaceuticals unit to enhance product launches ahead of a significant patent expiration [1] Group 1 - The company aims to bolster its product pipeline in anticipation of losing a crucial patent [1] - This strategic move is expected to improve the company's competitive position in the market [1] - The split of the pharmaceuticals unit is part of a broader strategy to optimize operations and focus on innovation [1]